OPKO Health (NASDAQ:OPK) Stock Rating Reaffirmed by HC Wainwright

OPKO Health (NASDAQ:OPK – Get Rating)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research report issued on Thursday, Benzinga reports. They currently have a $3.00 target price on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 141.94% from the stock’s current price.

OPKO Health Price Performance

NASDAQ:OPK opened at $1.24 on Thursday. The firm has a market cap of $958.09 million, a PE ratio of -2.82 and a beta of 1.64. OPKO Health has a 12 month low of $1.00 and a 12 month high of $3.78. The company has a quick ratio of 1.50, a current ratio of 1.85 and a debt-to-equity ratio of 0.13. The company’s 50-day moving average price is $1.27 and its two-hundred day moving average price is $1.58.

OPKO Health (NASDAQ:OPK – Get Rating) last released its quarterly earnings results on Thursday, February 23rd. The biotechnology company reported ($0.11) EPS for the quarter, meeting analysts’ consensus estimates of ($0.11). The firm had revenue of $185.40 million for the quarter, compared to analyst estimates of $168.21 million. OPKO Health had a negative net margin of 32.70% and a negative return on equity of 15.77%. The company’s revenue for the quarter was down 53.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.11) earnings per share. On average, equities analysts anticipate that OPKO Health will post -0.32 EPS for the current fiscal year.

Insider Transactions at OPKO Health

In related news, major shareholder Opko Health, Inc. bought 14,285,714 shares of OPKO Health stock in a transaction dated Thursday, January 26th. The shares were bought at an average cost of $0.35 per share, for a total transaction of $4,999,999.90. Following the completion of the transaction, the insider now owns 94,285,714 shares of the company’s stock, valued at $32,999,999.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Phillip Md Et Al Frost bought 1,000,000 shares of OPKO Health stock in a transaction dated Wednesday, March 8th. The shares were bought at an average cost of $1.18 per share, for a total transaction of $1,180,000.00. Following the completion of the transaction, the chief executive officer now owns 199,831,694 shares of the company’s stock, valued at $235,801,398.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Opko Health, Inc. bought 14,285,714 shares of OPKO Health stock in a transaction dated Thursday, January 26th. The shares were bought at an average price of $0.35 per share, for a total transaction of $4,999,999.90. Following the completion of the transaction, the insider now directly owns 94,285,714 shares of the company’s stock, valued at approximately $32,999,999.90. The disclosure for this purchase can be found here. 40.97% of the stock is owned by company insiders.

Institutional Investors Weigh In On OPKO Health

Institutional investors and hedge funds have recently modified their holdings of the business. Guggenheim Capital LLC bought a new stake in shares of OPKO Health during the first quarter worth approximately $38,000. Point72 Hong Kong Ltd bought a new stake in OPKO Health in the first quarter valued at approximately $39,000. Humankind Investments LLC bought a new stake in OPKO Health in the third quarter valued at approximately $25,000. Zacks Investment Management bought a new stake in OPKO Health in the third quarter valued at approximately $25,000. Finally, Beacon Pointe Advisors LLC bought a new stake in OPKO Health in the first quarter valued at approximately $49,000. 23.49% of the stock is owned by institutional investors.

OPKO Health Company Profile

(Get Rating)

OPKO Health, Inc is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment includes the clinical laboratory operations of BioReference, as well as point-of-care operations.